샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533656

세계의 세팔로스포린계 약제 시장

Cephalosporin Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 398 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세팔로스포린계 약제 시장은 2030년까지 223억 달러에 달할 전망입니다.

2023년에 188억 달러로 추정된 세팔로스포린계 약제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 2.4%로 성장하여 2030년에는 223억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 1세대 세팔로스포린계 약물은 복합 연간 성장률(CAGR) 1.6%로 성장을 지속하여, 분석 기간 종료 시 45억 달러에 달할 것으로 예측됩니다. 2세대 세팔로스포린계 약물 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 2.3%로 추정됩니다.

미국 시장은 51억 달러, 중국은 복합 연간 성장률(CAGR) 4.2%로 성장할 것으로 예측됩니다.

미국 세팔로스포린계 약물 시장은 2023년 51억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 42억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 4.2%를 나타낼 전망입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 1.2%와 2.1%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 1.5%로 성장할 것으로 예측됩니다.

세계의 세팔로스포린계 약물 시장 : 주요 동향과 촉진요인의 정리

세팔로스포린계 약물은 이전에 세팔로스포륨(Cephalosporium)으로 알려진 아크레모늄(Acremonium)균에서 유래된 베타락탐계 항생제의 큰 그룹입니다. 이 항생제는 5개의 세대로 분류되며, 각각은 보다 광범위한 박테리아를 표적으로 하고 저항성 박테리아의 발생에 대항하도록 설계되었습니다. 세팔렉신과 같은 1세대 세팔로스포린은 주로 그람 양성균과 일부 그람 음성균에 효과적입니다. 후세대가 됨에 따라, 이들 항생제는 그람 음성균에 대하여 더 높은 활성을 나타내게 되고, 베타 락타마제(많은 베타 락탐계 항생제를 불활성화할 수 있는 세균이 생산하는 효소)에 대한 내성도 강해집니다. 예를 들어 세프토리악손이나 세포탁심과 같은 세세대 세팔로스포린은 이전 세대에 내성을 가진 박테리아를 포함하여 광범위한 박테리아 감염에 높은 효과를 보입니다. 세프탈로린과 같은 5세대 세팔로스포린은 메티실린 내성 황색 포도상구균(MRSA) 및 기타 다제 내성 병원체를 대상으로 개발되어 항균제 요법의 큰 진보를 보이고 있습니다.

세팔로스포린계 약물의 개발과 사용은 박테리아 감염의 치료에 혁명을 일으키고 감염과의 싸움에 필수적인 수단을 제공했습니다. 이러한 약물은 폐렴, 요로 감염, 피부 감염, 패혈증 등의 치료에 임상 현장에서 널리 사용됩니다. 광역 스펙트럼 활성, 상대적으로 낮은 독성, 페니실린 시스템에 비해 적은 알레르기 반응으로 항생제 치료가 필요합니다. 또한, 세팔로스포린계 항균제는 수술 후 감염을 예방하기 위해 수술 현장에서 예방적으로 사용되는 경우가 많으며, 현대 의학에서 그 중요한 역할이 더욱 강조되고 있습니다. 그러나, 내성균의 지속적인 진화는 중대한 과제가 되고, 내성주와 효과적으로 싸우고, 이 중요한 약제의 지속적인 효능을 확보할 수 있는 새로운 세팔로스포린을 창출하기 위한 지속적 한 연구 개발이 필요합니다.

세팔로스포린계 약물 시장의 성장은 박테리아 감염의 유병률 증가 및 효과적이고 광범위한 항생제에 대한 수요 증가와 같은 여러 요인에 의해 야기됩니다. 의약품 개발에 있어서의 기술의 진보와, 이러한 항생제의 약동학적 또는 약역학적 프로파일을 개선하기 위한 지속적인 노력이 시장 확대에 크게 기여하고 있습니다. 박테리아 감염에 대한 신속하고 효과적인 치료를 추구하는 소비자의 행동은 항생제 내성의 세계 위협과 결합하여 새로운 세팔로스포린 개발에 대한 투자에 박차를 가하고 있습니다. 또한, 내성균에 대처하기 위한 신규 항생제 개발에 대한 규제 당국의 지원과 뒷받침은 승인과 상업화 과정을 가속화하고 있습니다. 헬스케어 인프라가 확대되고 신흥 시장에서 항생제가 입수하기 쉬워지고 있는 것도 시장의 성장을 더욱 뒷받침하고 있습니다. 이러한 요인들이 결합되어 세팔로스포린계 약물 시장의 지속적인 성장과 혁신이 보장되고, 감염 관리에서 현재와 미래의 과제를 해결하는 항생제의 중요성이 부각되고 있습니다.

조사 대상 기업 예(전 56건)

  • AbbVie, Inc.
  • Alkem Laboratories Limited
  • AristoPharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • China Union Chempharma(Suzhou) Co., Ltd.
  • Covalent Laboratories Pvt Ltd.
  • CSPC Pharmaceutical Group Co., Ltd.
  • Dhanuka Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Fujian Fukang Pharmaceutical Co., Ltd.
  • Hetero Healthcare Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.08.20

Global Cephalosporin Drugs Market to Reach US$22.3 Billion by 2030

The global market for Cephalosporin Drugs estimated at US$18.8 Billion in the year 2023, is expected to reach US$22.3 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. First Generation Cephalosporin Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Second Generation Cephalosporin Drugs segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 4.2% CAGR

The Cephalosporin Drugs market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Cephalosporin Drugs Market - Key Trends and Drivers Summarized

Cephalosporin drugs are a large group of beta-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as Cephalosporium. These antibiotics are classified into five generations, each designed to target a broader range of bacteria and to counteract the development of bacterial resistance. First-generation cephalosporins, such as cephalexin, are primarily effective against gram-positive bacteria and some gram-negative bacteria. As we move to later generations, these antibiotics exhibit enhanced activity against gram-negative bacteria and greater resistance to beta-lactamases, enzymes produced by bacteria that can deactivate many beta-lactam antibiotics. For instance, third-generation cephalosporins like ceftriaxone and cefotaxime are highly effective against a wide array of bacterial infections, including those resistant to earlier generations. Fifth-generation cephalosporins, such as ceftaroline, have been developed to target methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant pathogens, marking a significant advancement in antimicrobial therapy.

The development and use of cephalosporin drugs have revolutionized the treatment of bacterial infections, providing essential tools in the fight against infectious diseases. These drugs are widely used in clinical settings for the treatment of conditions such as pneumonia, urinary tract infections, skin infections, and septicemia. Their broad-spectrum activity, relatively low toxicity, and fewer allergic reactions compared to penicillins have made them a cornerstone in antibiotic therapy. Additionally, cephalosporins are often used prophylactically in surgical settings to prevent postoperative infections, further underscoring their critical role in modern medicine. The continued evolution of bacterial resistance, however, has posed significant challenges, necessitating ongoing research and development to create new cephalosporins that can effectively combat resistant strains and ensure the continued efficacy of these vital drugs.

The growth in the cephalosporin drugs market is driven by several factors, including the rising prevalence of bacterial infections and the increasing demand for effective and broad-spectrum antibiotics. Technological advancements in drug development and the continuous effort to improve the pharmacokinetic and pharmacodynamic profiles of these antibiotics have significantly contributed to market expansion. Consumer behavior towards seeking prompt and effective treatment for bacterial infections, coupled with the global threat of antibiotic resistance, has spurred investment in the development of new cephalosporins. Additionally, regulatory support and the push for the development of novel antibiotics to address resistant strains have accelerated the approval and commercialization processes. The expansion of healthcare infrastructure and the increasing accessibility of antibiotics in emerging markets further drive market growth. These factors collectively ensure the sustained growth and innovation within the cephalosporin drugs market, highlighting the importance of these antibiotics in addressing current and future challenges in infectious disease management.

Select Competitors (Total 56 Featured) -

  • AbbVie, Inc.
  • Alkem Laboratories Limited
  • AristoPharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • China Union Chempharma (Suzhou) Co., Ltd.
  • Covalent Laboratories Pvt Ltd.
  • CSPC Pharmaceutical Group Co., Ltd.
  • Dhanuka Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Fujian Fukang Pharmaceutical Co., Ltd.
  • Hetero Healthcare Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Cephalosporin Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Antibiotic Resistance and Its Implications for Cephalosporin Efficacy
    • Development of New Generation Cephalosporins to Combat Resistant Strains
    • Growing Demand for Broad-Spectrum Antibiotics in Clinical Settings
    • Global Increase in Bacterial Infections Driving Demand for Effective Treatments
    • Advances in Microbial Diagnostics Support Targeted Antibiotic Use
    • Market Challenges Posed by Generic Drug Competition
    • Research on Cephalosporin Use in Veterinary Medicine Expanding Market Dimensions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cephalosporin Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cephalosporin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fourth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fourth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fourth Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Fifth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Fifth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Fifth Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Skin Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Skin Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Skin Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Sexually Transmitted Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Urinary Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Respiratory Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Injection Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Injection Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Injection Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cephalosporin Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cephalosporin Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cephalosporin Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cephalosporin Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제